KR101475311B1 - 항암 활성을 갖는 화합물 - Google Patents

항암 활성을 갖는 화합물 Download PDF

Info

Publication number
KR101475311B1
KR101475311B1 KR1020097023566A KR20097023566A KR101475311B1 KR 101475311 B1 KR101475311 B1 KR 101475311B1 KR 1020097023566 A KR1020097023566 A KR 1020097023566A KR 20097023566 A KR20097023566 A KR 20097023566A KR 101475311 B1 KR101475311 B1 KR 101475311B1
Authority
KR
South Korea
Prior art keywords
amino
dione
delete delete
trifluoromethyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097023566A
Other languages
English (en)
Korean (ko)
Other versions
KR20090128560A (ko
Inventor
타쿠미 카와베
마치요 이시가키
타쿠지 사토
사야카 야마모토
요코 하세가와
Original Assignee
가부시키가이샤 캔버스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 캔버스 filed Critical 가부시키가이샤 캔버스
Publication of KR20090128560A publication Critical patent/KR20090128560A/ko
Application granted granted Critical
Publication of KR101475311B1 publication Critical patent/KR101475311B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020097023566A 2007-04-11 2008-04-11 항암 활성을 갖는 화합물 Active KR101475311B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91125807P 2007-04-11 2007-04-11
US60/911,258 2007-04-11

Publications (2)

Publication Number Publication Date
KR20090128560A KR20090128560A (ko) 2009-12-15
KR101475311B1 true KR101475311B1 (ko) 2014-12-23

Family

ID=39939984

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097023566A Active KR101475311B1 (ko) 2007-04-11 2008-04-11 항암 활성을 갖는 화합물

Country Status (17)

Country Link
US (2) US8084454B2 (enExample)
EP (4) EP4074704A1 (enExample)
JP (2) JP5635396B2 (enExample)
KR (1) KR101475311B1 (enExample)
CN (2) CN101720323A (enExample)
AU (1) AU2008294410B2 (enExample)
BR (2) BRPI0810911B1 (enExample)
CA (4) CA2684037C (enExample)
DK (2) DK3567035T3 (enExample)
ES (3) ES2927954T3 (enExample)
HU (2) HUE029370T2 (enExample)
IL (4) IL289165B2 (enExample)
MX (3) MX391154B (enExample)
NZ (1) NZ580237A (enExample)
RU (1) RU2482111C2 (enExample)
WO (1) WO2009031040A2 (enExample)
ZA (1) ZA200906960B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3567035T3 (da) * 2007-04-11 2022-09-05 Canbas Co Ltd N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
EP2304436A1 (en) 2008-07-10 2011-04-06 Nodality, Inc. Methods for diagnosis, prognosis and treatment
CN102405044A (zh) * 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
US20100215644A1 (en) * 2009-02-25 2010-08-26 Nodality, Inc. A Delaware Corporation Analysis of nodes in cellular pathways
CN104744215B (zh) 2010-03-03 2019-03-15 尼昂克技术公司 包含单萜的药物组合物
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
CN110464718A (zh) 2010-08-27 2019-11-19 尼昂克技术公司 包含poh衍生物的药物组合物
EP2651864B1 (en) 2010-12-17 2016-07-13 Neonc Technologies Inc. Methods and devices for using isoperillyl alcohol
WO2013020024A2 (en) * 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
US9814693B2 (en) 2012-05-09 2017-11-14 Delmar Pharmaceuticals, Inc. Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
KR20150021036A (ko) 2012-06-14 2015-02-27 다이이찌 산쿄 가부시키가이샤 피페리디닐피라졸로피리딘 유도체
US9682995B2 (en) 2013-01-30 2017-06-20 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
WO2016090355A2 (en) * 2014-12-05 2016-06-09 Massachusetts Institute Of Technology Catechol-rich polymers from n-substituted maleimides
EP4219457A1 (en) 2015-01-26 2023-08-02 Ottawa Hospital Research Institute 3-(2h)-pyridazinone derivatives, their compositions and methods for viral sensitization
CN107613768B (zh) 2015-02-12 2020-10-20 NeOnc技术股份有限公司 包含紫苏醇衍生物的药物组合物
BR112018068681A2 (pt) 2016-03-16 2019-01-15 Bayer Cropscience Ag derivados de n-(cianobenzil)-6-(ciclopropil-carbonilamino)-4-(fenil)-piridina-2-carboxamida e compostos relacionados como pesticidas e agentes de proteção de plantas
USD915100S1 (en) 2016-03-31 2021-04-06 Ocean 22, Llc Spooled item holding device
USD801721S1 (en) 2016-03-31 2017-11-07 Patricia Grayson Briden Spooled item holding device
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
EP3746065A4 (en) 2018-01-29 2022-02-16 Cognos Therapeutics Inc. INTRATUMORAL ADMINISTRATION OF BORTEZOMIB
EP3746451B1 (en) 2018-02-02 2023-07-12 Boehringer Ingelheim International GmbH Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
WO2019149660A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
EP3749291B1 (en) 2018-02-08 2024-01-03 University of Southern California Methods of permeabilizing the blood brain barrier
EP4153599B1 (en) 2020-05-22 2024-03-13 Boehringer Ingelheim International GmbH Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
WO2021233884A1 (en) 2020-05-22 2021-11-25 Boehringer Ingelheim International Gmbh Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
EP4415700A1 (en) * 2021-10-15 2024-08-21 The Curators of the University of Missouri Inhibitors of p1b-type atpases
CN114425054A (zh) * 2022-01-20 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途
CN120247782B (zh) * 2025-06-04 2025-08-19 北京颖泰嘉和生物科技股份有限公司 氟吡菌酰胺类化合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009325A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
WO2005024755A2 (en) * 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5564557A (en) * 1978-11-08 1980-05-15 Mitsui Toatsu Chem Inc Diphenyl ether compound and herbicide containing the same
IL81307A0 (en) * 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
US5635966A (en) * 1994-01-11 1997-06-03 Hewlett-Packard Company Edge feed ink delivery thermal inkjet printhead structure and method of fabrication
JPH07224032A (ja) 1994-02-09 1995-08-22 Mitsui Petrochem Ind Ltd Ｎ−アリールオキシフタルイミド誘導体、その製造方 法及びそれを有効成分として含有する除草剤
JPH07244032A (ja) * 1994-03-01 1995-09-19 Ishikawajima Harima Heavy Ind Co Ltd 溶接部検査装置
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
CA2245029A1 (en) * 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6205557B1 (en) 1998-06-09 2001-03-20 At&T Corp. Redundant call processing
US6476061B1 (en) * 1998-11-24 2002-11-05 Basf Aktiengesellschaft Fungicides containing pyrrolidones as their active agents
DE60019318T2 (de) 1999-09-22 2006-03-09 Canbas Co., Ltd., Numazu Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
CA2400224A1 (en) * 2000-02-26 2001-08-30 Basf Aktiengesellschaft Fungicidal agents containing pyrrolidones as their active agents and use thereof for treating plants
JP2002318434A (ja) * 2001-04-23 2002-10-31 Konica Corp ハロゲン化銀写真感光材料、処理方法、および画像形成方法
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4919598B2 (ja) * 2002-06-06 2012-04-18 株式会社 キャンバス Ｄｎａ損傷誘発性細胞周期ｇ２チェックポイントを排除し、そして／またはｄｎａ損傷処置の抗癌活性を増強する化合物
WO2005011573A2 (en) * 2003-08-01 2005-02-10 Auspex Pharmaceuticals, Inc. Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
US7932281B2 (en) * 2004-03-10 2011-04-26 Kureha Corporation Amine-based compound and use thereof
US7973061B2 (en) * 2004-03-31 2011-07-05 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
AU2006212951A1 (en) * 2005-02-08 2006-08-17 Merck & Co., Inc. Inhibitors of checkpoint kinases
WO2007022241A2 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity quinoline-based kinase ligands
EP1960386A2 (en) * 2005-11-01 2008-08-27 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
EP2005957B1 (en) * 2006-03-31 2012-05-30 Takeda Pharmaceutical Company Limited Acid secretion inhibitor
WO2008110891A2 (en) 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
DK3567035T3 (da) * 2007-04-11 2022-09-05 Canbas Co Ltd N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009325A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
WO2005024755A2 (en) * 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes

Also Published As

Publication number Publication date
EP4074704A1 (en) 2022-10-19
HK1139143A1 (zh) 2010-09-10
HUE059861T2 (hu) 2023-01-28
WO2009031040A2 (en) 2009-03-12
ES2927954T3 (es) 2022-11-14
RU2482111C2 (ru) 2013-05-20
CA2684037A1 (en) 2009-03-12
DK3567035T3 (da) 2022-09-05
US20080275057A1 (en) 2008-11-06
NZ580237A (en) 2012-06-29
EP3567035B1 (en) 2022-06-01
CA3030510A1 (en) 2009-03-12
CA3030510C (en) 2023-03-14
CA2913840C (en) 2019-03-05
CA2684037C (en) 2016-02-16
US8415357B2 (en) 2013-04-09
ES2732230T3 (es) 2019-12-12
CN105175394B (zh) 2018-06-08
IL242883B (en) 2022-01-01
BR122022005149B1 (pt) 2022-09-27
JP2010523644A (ja) 2010-07-15
CN101720323A (zh) 2010-06-02
EP2152692B9 (en) 2020-03-25
CN105175394A (zh) 2015-12-23
JP2014012706A (ja) 2014-01-23
EP3088397A1 (en) 2016-11-02
IL289165B2 (en) 2024-05-01
IL289165B1 (en) 2024-01-01
IL309201A (en) 2024-02-01
AU2008294410A1 (en) 2009-03-12
EP3088397B1 (en) 2019-04-10
AU2008294410B2 (en) 2012-09-06
RU2009141619A (ru) 2011-05-20
US20110092514A1 (en) 2011-04-21
US8084454B2 (en) 2011-12-27
BRPI0810911A2 (pt) 2021-03-30
EP2152692A2 (en) 2010-02-17
EP3567035A1 (en) 2019-11-13
KR20090128560A (ko) 2009-12-15
IL201380A0 (en) 2010-05-31
HUE029370T2 (hu) 2017-02-28
JP5635396B2 (ja) 2014-12-03
BRPI0810911B1 (pt) 2022-05-17
MX2009011025A (es) 2010-01-25
IL289165A (en) 2022-02-01
ES2594704T3 (es) 2016-12-22
ZA200906960B (en) 2010-12-29
DK2152692T3 (en) 2016-09-26
CA2913840A1 (en) 2009-03-12
CA3188320A1 (en) 2009-03-12
MX2020009403A (es) 2022-03-31
EP2152692B1 (en) 2016-06-15
WO2009031040A3 (en) 2009-05-14
MX374896B (es) 2025-03-04
MX391154B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
KR101475311B1 (ko) 항암 활성을 갖는 화합물
CN101784543B (zh) 作为细胞坏死抑制剂的吲哚和吲唑化合物
CN109803972B (zh) 1h-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
WO2020156243A1 (zh) Shp2抑制剂及其应用
WO2020156242A1 (zh) Shp2抑制剂及其应用
WO2015158310A1 (zh) 一种酪氨酸激酶抑制剂及其用途
WO2022156758A1 (zh) 新型酰胺吡咯类化合物及其在药物中的用途
CN105636956B (zh) 作为细胞坏死阻碍剂的吲哚化合物
HK40083024A (en) Quinoline compounds with anti-cancer activity
HK1139143B (en) Compounds with anti-cancer activity
HK40039964A (en) Tricyclic compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091111

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120831

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140123

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140823

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140123

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20140922

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140823

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20141111

Appeal identifier: 2014101005879

Request date: 20140922

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140922

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140922

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20140327

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20120831

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20141111

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20141024

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20141216

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20141217

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20171208

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20171208

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20181207

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20191206

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20201204

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20211203

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20221027

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20241029

Start annual number: 11

End annual number: 11